Yang Guoli, Luo Yue, Ma Kanghua, Yang Bao, Tang Ping, Zhang Min, Dong Qian, Mao Min
Department of Cardiology, the First Affiliated Hospital of Chongqing Medical University, Chongqing, China.
Department of Cardiology, the Southwest Hospital of Army Medical University (AMU), Chongqing, China.
Cardiovasc Diagn Ther. 2025 Feb 28;15(1):100-115. doi: 10.21037/cdt-24-410. Epub 2025 Feb 25.
Lipoprotein(a) [Lp(a)] levels and diabetic status have been recognized as risk factors for atherosclerosis. However, no studies on atherosclerosis have integrated these two indicators. This study aimed to evaluate the relationship between Lp(a) levels, diabetic status, and their combined effects on subclinical atherosclerosis.
This cross-sectional study included patients presenting with a first episode of chest pain at the First Affiliated Hospital of Chongqing Medical University from June 2018 to February 2022. All participants underwent coronary computed tomography angiography (CCTA) and carotid ultrasound to evaluate subclinical atherosclerosis. Logistic regression analysis was used to examine the associations of Lp(a) levels and diabetic status-both individually and in combination-with coronary artery calcium (CAC) and carotid arteriopathy.
Among 912 patients, 473 (51.9%) had CAC and 637 (69.8%) had carotid arteriopathy. After adjusting the confounding variables, elevated Lp(a) levels associated with CAC [odds ratio (OR) 1.51, 95% confidence interval (CI): 1.02-2.24, P=0.040] and carotid arteriopathy (OR 1.77, 95% CI: 1.10-2.86, P=0.02) were statistically significant. After combining diabetic status, almost all Lp(a) levels were significantly associated with CAC and CAC score categories (CAC scores: 0.1-99.9, 100-399.9, ≥400) in the diabetes mellitus (DM) group. In this group, the highest risk for CAC and the most severe CAC score categories were observed in patients with Lp(a) levels of >300 mg/L. Among patients with DM, in the lower Lp(a) level group, the prevalence and severity of CAC were more pronounced than those in the medium Lp(a) level group. Additionally, in patients with DM only, elevated Lp(a) levels were associated with carotid arteriopathy (OR 3.38, 95% CI: 1.24-9.20; P=0.02), increased carotid intima-media thickness (cIMT; OR 3.67, 95% CI: 1.10-12.30; P=0.04), and stable/vulnerable carotid plaque (OR 3.39, 95% CI: 1.09-10.55; P=0.04; OR 3.21, 95% CI: 1.07-9.65; P=0.04). However, there were no significant differences between prediabetes and CAC or carotid arteriopathy.
In patients with chest pain and DM without cardiovascular disease (CVD), Lp(a) level was significantly associated with subclinical atherosclerosis and had a synergistic effect with DM. Notably, lower Lp(a) levels in patients with DM may lead to an additional subclinical atherosclerosis risk, whereas prediabetes does not show the same association. Therefore, these findings highlight the importance of formulating early preventive strategies for subclinical atherosclerosis based on Lp(a) levels and diabetic status.
脂蛋白(a)[Lp(a)]水平和糖尿病状态已被确认为动脉粥样硬化的危险因素。然而,尚无关于动脉粥样硬化的研究将这两个指标整合起来。本研究旨在评估Lp(a)水平、糖尿病状态及其对亚临床动脉粥样硬化的联合影响之间的关系。
这项横断面研究纳入了2018年6月至2022年2月在重庆医科大学附属第一医院首次出现胸痛的患者。所有参与者均接受冠状动脉计算机断层扫描血管造影(CCTA)和颈动脉超声检查以评估亚临床动脉粥样硬化。采用逻辑回归分析来检验Lp(a)水平和糖尿病状态——单独及联合——与冠状动脉钙化(CAC)和颈动脉病变的关联。
在912例患者中,473例(51.9%)有CAC,637例(69.8%)有颈动脉病变。在调整混杂变量后,Lp(a)水平升高与CAC[比值比(OR)1.51,95%置信区间(CI):1.02-2.24,P=0.040]和颈动脉病变(OR 1.77,95%CI:1.10-2.86,P=0.02)相关,差异有统计学意义。合并糖尿病状态后,糖尿病(DM)组中几乎所有Lp(a)水平均与CAC及CAC评分类别(CAC评分:0.1-99.9、100-399.9、≥400)显著相关。在该组中,Lp(a)水平>300 mg/L的患者发生CAC的风险最高,且CAC评分类别最严重。在DM患者中,在较低Lp(a)水平组中,CAC的患病率和严重程度比中等Lp(a)水平组更明显。此外,仅在DM患者中,Lp(a)水平升高与颈动脉病变(OR 3.38,95%CI:1.24-9.20;P=0.02)、颈动脉内膜中层厚度(cIMT)增加(OR 3.67,95%CI:1.10-12.30;P=0.04)以及稳定/易损颈动脉斑块(OR 3.39,95%CI:1.09-10.55;P=0.04;OR 3.21,95%CI:1.07-9.65;P=0.04)相关。然而,糖尿病前期与CAC或颈动脉病变之间无显著差异。
在无心血管疾病(CVD)的胸痛和DM患者中,Lp(a)水平与亚临床动脉粥样硬化显著相关,并与DM有协同作用。值得注意的是,DM患者中较低的Lp(a)水平可能导致额外的亚临床动脉粥样硬化风险,而糖尿病前期则未显示出相同的关联。因此,这些发现凸显了根据Lp(a)水平和糖尿病状态制定亚临床动脉粥样硬化早期预防策略的重要性。